Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus dosing algorithm in pediatric renal transplant recipients
2017-001681-24Phase 4Terminated
- Sponsor
- Erasmus MC
- Start
- Aug 2017
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of tacrolimus in kidney transplant and kidney allograft rejection, sponsored by Erasmus MC. Primary endpoint: Proportion of patients reaching target tacrolimus C0 (10-15 ng/mL) on day 3. Started Aug 2017; status: terminated.
02
Drugs
tacrolimus
03
Conditions
kidney transplantkidney allograft rejection
Beyond the preview
Go deeper on 2017-001681-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001681-24.